●Therapeutic potential of oral tolerance. Mayer, L. & Shao, L. Nature Reviews Immunology June (2004)

Psychedelic drugs: the ups and downs of ecstasy. Check, E. Nature 13 May (2004)

●Next-generation protein drugs. Tomlinson, I. M. Nature Biotechnology May (2004)

●Polio eradication, cessation of vaccination and re-emergence of disease. Minor, P. D. Nature Reviews Microbiology June (2004)

●Exploiting tumour hypoxia in cancer treatment. Brown, J. M. & Wilson, W. R. Nature Reviews Cancer June (2004)

●Structure-aided drug design's next generation. Thiel, K. A. Nature Biotechnology May (2004)

●Can innate immunity be enhanced to treat microbial infections? Finlay, B. B. & Hancock, R. E. W. Nature Reviews Microbiology June (2004)

●Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Sugamura, K., Ishii, N. & Weinberg, A. D. Nature Reviews Immunology June (2004)

●Tracking and teaching. Hadley, C. EMBO Reports June (2004) Rather than waiting for new drugs, surveillance and education might be more efficient strategies to combat antimicrobial resistance.

●The potential of positron-emission tomography to study anticancer-drug resistance. West, C. M. L., Jones, T. & Price, P. Nature Reviews Cancer June (2004)

●Finally, mice with CF lung disease. Frizzell, R. A. & Pilewski, J. M. Nature Medicine May (2004)

●LIFE and SCOPE: what guidance do they offer alongside ALLHAT and ANBP2? Nicholls, M. G. Journal of Human Hypertension May (2004)

●Yeast as a model system for anticancer drug discovery. Simon, J. A. & Bedalov, A. Nature Reviews Cancer June (2004)

The anti-angiogenic basis of metronomic chemotherapy. Kerbel, R. S. & Kamen, B. A. Nature Reviews Cancer June (2004)